143 related articles for article (PubMed ID: 22730513)
1. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
Khoury N; Chang J; Gru AA; Whyte MP
J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
[TBL] [Abstract][Full Text] [Related]
2. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
Booth KA; Hays CI
J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
[TBL] [Abstract][Full Text] [Related]
3. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease.
Grasemann C; Schündeln MM; Hövel M; Schweiger B; Bergmann C; Herrmann R; Wieczorek D; Zabel B; Wieland R; Hauffa BP
J Clin Endocrinol Metab; 2013 Aug; 98(8):3121-6. PubMed ID: 23788687
[TBL] [Abstract][Full Text] [Related]
4. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
Cicci JD; Buie L; Bates J; van Deventer H
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e207-11. PubMed ID: 25128013
[No Abstract] [Full Text] [Related]
5. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
6. Denosumab for post-transplantation hypercalcemia in osteopetrosis.
Shroff R; Beringer O; Rao K; Hofbauer LC; Schulz A
N Engl J Med; 2012 Nov; 367(18):1766-7. PubMed ID: 23113501
[No Abstract] [Full Text] [Related]
7. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia in idiopathic myelofibrosis: modulation of calcium and collagen homeostasis by 1,25-dihydroxyvitamin D3.
Voss A; Schmidt K; Hasselbalch H; Junker P
Am J Hematol; 1992 Mar; 39(3):231-3. PubMed ID: 1546720
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon].
Gotić M; Cvetković M; Bozanović T; Cemerikić V
Srp Arh Celok Lek; 2001; 129(11-12):304-8. PubMed ID: 11928616
[TBL] [Abstract][Full Text] [Related]
11. Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
Freeman A; El-Amm J; Aragon-Ching JB
Clin Genitourin Cancer; 2013 Dec; 11(4):e24-6. PubMed ID: 24007982
[No Abstract] [Full Text] [Related]
12. [Hypercalcemia in myeloma].
Abe M
Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268
[TBL] [Abstract][Full Text] [Related]
13. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
14. [Refractory hypercalcemia in patient with lung cancer].
Grzywacz A; Dziuk M; Niemczyk S
Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
[TBL] [Abstract][Full Text] [Related]
15. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
16. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
17. Denosumab may reduce hypercalcaemia after transplantation for osteopetrosis.
BMJ; 2012 Nov; 345():e7477. PubMed ID: 23135199
[No Abstract] [Full Text] [Related]
18. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
19. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
20. Acute myelofibrosis and malignant hypercalcemia.
Libnoch JA; Ajlouni K; Millman WL; Guansing AR; Theil GB
Am J Med; 1977 Mar; 62(3):432-8. PubMed ID: 842561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]